Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Nine ...

The latest trading session saw Okta (OKTA) ending at $97.47, denoting a +0.02% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.36%. Elsewhere, ...

We recently published a list of Top 10 AI Stocks to Watch Amid US-China AI War. In this article, we are going to take a look ...

JPMorgan began coverage of Jamf Holding Corp. (NASDAQ: NASDAQ:JAMF), currently trading at $15.45 with a market capitalization of $1.98 billion, with an Overweight rating, setting a price target of $20 ...

Scotiabank analyst Patrick Colville reiterated a Hold rating on Okta (OKTA – Research Report) today and set a price target of $94.00. The ...

In a report released today, Saket Kalia from Barclays maintained a Hold rating on Okta (OKTA – Research Report), with a price target of $96.00.

In a report released today, Trevor J. Walsh from JMP Securities maintained a Hold rating on Okta (OKTA – Research Report). The company’s shares ...

Okta, Inc (NASDAQ:OKTA) received a reiterated Hold rating from Jefferies, with a steady price target of $90.00. Trading at ...

Jefferies reiterated a Hold rating and $90 price target on Okta (OKTA) after the company announced a roughly 3% cut in its workforce. Based on ...

Inc. the identity and access management company, has confirmed its financial outlook for the fourth quarter and the fiscal year ending January 31, 2025. The reaffirmation of these projections aligns ...

Okta's recovery from its 2021-2022 decline is driven by significant R&D investments. Click here to read why I maintain a Buy ...

Okta's strong free cash flow, high gross margins, and stable subscription base outweigh short-term issues. Read why OKTA ...